11 recruiting, 3 active not recruiting, 3 completed, 2 not yet recruiting. 9 Phase 1, 6 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Recruiting 4, Active not recruiting 2, Completed 2, Not yet recruiting 1 |
| Phase 3 | 6 | Recruiting 5, Not yet recruiting 1 |
| Phase 2 | 4 | Recruiting 2, Active not recruiting 1, Completed 1 |
Follow Eloralintide: new trials by email Literature Review of Eloralintide trials Research Report on Eloralintide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of EloraTZP in Adult Participants With Obesity Without Type 2 Diabetes eloralintide and tirzepatide, Eloralintide, Tirzepatide - Obesity | Phase 3 | Not yet recruiting | Eli Lilly and Company | 2115 | 2026-12-01 | 2026-10-19 |
| A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes Macupatide, Eloralintide, Placebo - Obesity, Overweight | Phase 1 | Not yet recruiting | Eli Lilly and Company | 60 | 2026-10-01 | 2026-08-14 |
| A Study of Eloralintide (LY3841136) in Female Participants With Obesity or Overweight Eloralintide, Combined oral contraceptive - Obesity, Overweight | Phase 1 | Recruiting | Eli Lilly and Company | 34 | 2026-09-15 | 2026-10-08 |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight Eloralintide, Placebo, Acetaminophen - Obesity, Overweight | Phase 1 | Recruiting | Eli Lilly and Company | 56 | 2026-07-31 | 2026-08-20 |
| A Study of Eloralintide (LY3841136) in Healthy Participants Eloralintide - Healthy Volunteers | Phase 1 | Active not recruiting | Eli Lilly and Company | 58 | 2026-07-20 | 2026-09-29 |
| A Study of Eloralintide (LY3841136) in Participants With Overweight or Obesity Eloralintide, Placebo - Overweight, Obesity | Phase 1 | Recruiting | Eli Lilly and Company | 115 | 2026-06-24 | 2026-07-16 |
| A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight Macupatide, Eloralintide, Placebo - Overweight, Obesity | Phase 2 | Recruiting | Eli Lilly and Company | 400 | 2026-05-15 | 2026-10-08 |
| A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function LY3841136 - Kidney Disease, Renal Insufficiency Chronic | Phase 1 | Active not recruiting | Eli Lilly and Company | 28 | 2026-02-24 | 2026-08-19 |
| A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight Eloralintide, Placebo - Sleep Apnea, Obstructive, Obesity | Phase 3 | Recruiting | Eli Lilly and Company | 800 | 2026-02-10 | 2026-10-08 |
| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin Eloralintide, Placebo - Overweight, Obesity | Phase 3 | Recruiting | Eli Lilly and Company | 900 | 2026-02-10 | 2026-09-22 |
| A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. LY3841136 - Hepatic Insufficiency | Phase 1 | Recruiting | Eli Lilly and Company | 36 | 2026-02-10 | 2026-06-04 |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight Eloralintide, Placebo - Osteoarthritis, Overweight or Obesity | Phase 3 | Recruiting | Eli Lilly and Company | 900 | 2026-02-09 | 2026-10-08 |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes Eloralintide, Placebo - Obesity, Overweight | Phase 3 | Recruiting | Eli Lilly and Company | 1980 | 2026-02-06 | 2026-09-22 |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes Eloralintide, Placebo - Overweight, Obesity | Phase 3 | Recruiting | Eli Lilly and Company | 1035 | 2025-12-15 | 2026-10-08 |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes Macupatide, Eloralintide, Macupatide Placebo - Obesity, Overweight | Phase 2 | Active not recruiting | Eli Lilly and Company | 200 | 2025-10-16 | 2026-10-09 |
| A Study of Eloralintide (LY3841136) in Chinese Participants With Obesity or Overweight Eloralintide, Placebo - Obesity, Overweight | Phase 1 | Completed | Eli Lilly and Company | 30 | 2025-04-21 | 2025-11-19 |
| A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity Eloralintide and Tirzepatide, Eloralintide - Overweight, Obesity | Phase 1 | Completed | Eli Lilly and Company | 188 | 2025-04-09 | 2026-01-30 |
| A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight Eloralintide, Placebo - Obesity, Overweight | Phase 2 | Completed | Eli Lilly and Company | 263 | 2024-02-05 | 2026-06-24 |
| A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight LY3305677, LY3841136, Tirzepatide - Obesity, Overweight | Phase 2 | Recruiting | Eli Lilly and Company | 1481 | 2023-11-17 | 2026-10-07 |
Obesity (16) · Overweight (15) · Diabetes Mellitus, Type 2 (2) · Hepatic Insufficiency (1) · Kidney Diseases (1) · Kidney Failure, Chronic (1) · Osteoarthritis (1) · Overnutrition (1) · Renal Insufficiency (1) · Renal Insufficiency, Chronic (1) · Sleep Apnea, Obstructive (1)
United States (16) · Japan (7) · China (6) · Germany (6) · Puerto Rico (6) · Argentina (5) · India (5) · South Korea (5) · Taiwan (5) · Australia (4) · Brazil (4) · Belgium (3) · Canada (3) · Czechia (3) · Spain (3)
2025 (7)